Search Images Maps Play YouTube News Gmail Drive More »
Settings | Sign in


Delhi High Court asks Roche to explain lawsuit over Avastin copy

Economic Times - ‎May 24, 2016‎
Roche's Avastin has raked in $7 billion in global sales. The drug treats debilitating ailments like colorectal cancer, non-small cell lung cancer, kidney cancer and ovarian cancer.

Roche's Avastin approved in Japan for cervical cancer

Seeking Alpha - ‎May 24, 2016‎
Chugai Pharmaceutical Co. (OTC:CHGCF)(OTCPK:CHGCY), majority-owned by Roche (OTCQX:RHHBY), announces that the Japanese Ministry of Health, Labour and Welfare has approved the use of Avastin (bevacizumab) for the treatment of advanced or ...

Roche's reputation at stake if Avastin biosimilar approved without trial: Kapil Sibal

Economic Times - ‎May 21, 2016‎
Roche's Avastin has raked in $7 billion in global sales. The drug treats debilitating ailments like colorectal cancer, non-small cell lung cancer, kidney cancer and ovarian cancer.

Will biosim naming hit Roche's Avastin rep? Delhi Court doesn't buy it

FiercePharma - ‎May 23, 2016‎
A former law minister in India arguing for Swiss drugmaker Roche ($RHBBY) has been asked by the Delhi High Court to compile a brief supporting claims that the company faces reputational risk if an Indian firm uses the ingredient name of its major ...

Chugai's Avastin gets Japanese nod for additional indication of advanced/recurrent cervical cancer - ‎May 23, 2016‎
In Japan, Avastin is currently marketed for the indications of “unresectable advanced or recurrent colorectal cancer,” “unresectable advanced or recurrent non-squamous non-small cell lung cancer,” “inoperable or recurrent breast cancer,” “malignant ...

Roche presses on biosimilar labels in India with Avastin challenge

FiercePharma - ‎May 18, 2016‎
The Economic Times reports that the Swiss-based firm has filed a lawsuit in the Delhi High Court against the Drug Controller General of India to block any approval of a biosimilar label for Hyderabad-based Hetero Drugs in the case of bevacizumab ...

Roche moves court to block copies of cancer drug Avastin, A La Herceptin

Economic Times - ‎May 15, 2016‎
MUMBAI: Swiss biotechnology giant Roche has sued the Drug Controller General of India in Delhi High Court along with Hyderabad-based Hetero Drugs over the process followed for approval of copies of complex biotech drugs or biosimilars of Avastin ...

Roche continues generics battle with latest lawsuit over Avastin copies

BioPharma Dive - ‎May 18, 2016‎
Roche is attempting to block the entry of copies of its major cancer drug Avastin in India, suing India's Drug Controller General and generics maker Hetero Drugs in Delhi High Court, the Economic Times reports.

Samsung Bioepis to begin global phase-III trials for Avastin biosimilar

The Korea Herald - ‎May 17, 2016‎
Samsung Bioepis is scheduled to begin its final stage of clinical trials for SB8, its new biosimilar drug referencing Roche's blockbuster cancer treatment Avastin (bevacizumab), around the world. According to the EU Clinical Trials Register, Samsung ...

A Global Phase III Trial for Avastin Biosimilar Has Begun

JD Supra (press release) - ‎May 13, 2016‎
Samsung Bioepis - the joint venture between Samsung and Biogen Idec - has started a phase III clinical trial for a biosimilar version of Roche's cancer drug Avastin (bevacizumab). Bevacizumab slows the growth of new blood vessels in tumors and is used ...

Presse: la filiale de Roche Chugai obtient une extension pour Avastin - ‎May 23, 2016‎
Presse: la filiale de Roche Chugai obtient une extension pour Avastin. Zurich (awp) - Roche, via sa filiale Chugai, aurait obtenu une extension de l'homologation pour le médicament Avastin. Le ministère japonais de la Santé a autorisé le produit pour ...
See realtime coverage

Pharmalot, Pharmalittle: Sanofi moves to replace the Medivation board

STAT - ‎11 hours ago‎
India's Delhi High Court has again asked Roche to explain why it is suing the Drug Controller General of India and Hetero Drugs over the approval of a biosimilar version of its Avastin breast cancer drug, the Economic Times says. Roche argued that ...

DelMar Pharmaceuticals Announces Successful Completion of End-of-Phase 2 Meeting with FDA on VAL-083 for the ...

PR Newswire (press release) - ‎10 hours ago‎
"We are pleased with the FDA's guidance on our Phase 3 trial design in patients with glioblastoma who have failed prior therapy with temozolomide and bevacizumab (Avastin®), and we look forward to finalizing the trial design and initiating the study as ...
See realtime coverage

If you get colon cancer, your prognosis depends partly on where it started

Washington Post - ‎May 18, 2016‎
Specifically, patients with right-side tumors who were given Avastin survived for 24.2 months compared with 16.7 months for those treated with Erbitux.

New migraine drugs promise relief — but at a steep price

The Verge - ‎May 24, 2016‎
For instance, Genentech's Avastin, which is used to treat cancer, can cost $50,000 a year. Alexion's Soliris, which treats a rare immune disorder, has been dubbed by Forbes as "the world's single most expensive drug" and can cost as much as $400,000 a ...
See realtime coverage

US FDA accepts Samsung Bioepis infliximab biosim for review

FiercePharma - ‎May 24, 2016‎
... Sanofi's ($SNY) blockbuster insulin Lantus (insulin glargine), AbbVie's ($ABBV) autoimmune treatment Humira (adalimumab), Roche's ($RHHBY) breast cancer drug Herceptin (trastuzumab) and its multicancer drug Avastin (bevacizumab)--with another 7 ...
See realtime coverage

Eli Lilly and Co: Next Decade's Most Diversified Global Drug Leader

Business Finance News - ‎8 hours ago‎
The patent cliff is playing a major role as most blockbuster drugs have either lost their patents or will lose it in the near future such as Herceptin, Erbitux, Rituxan, and Avastin. This patent expiration will boost the therapeutic market due to the ...

Tributes paid to 'brave' and 'inspirational' cancer campaigner

WalesOnline - ‎May 24, 2016‎
In 2013 she decided to rent a room in London to receive treatment from the Royal Marsden Hospital after she was told by her Welsh health board that the drug Avastin was unavailable. She went on to lobby the national and Welsh Governments to promote ...
See realtime coverage

As Gates Foundation leader, her target is health care

Houston Chronicle - ‎May 24, 2016‎
Before joining the foundation, she led development of the cancer drugs Avastin and Herceptin at Genentech, then was chancellor of the University of California, San Francisco.

Cell Medica Expands Management Team with Experienced Pharmaceutical Executives

Business Wire (press release) - ‎May 24, 2016‎
Dr. Pralong also held key biotech manufacturing positions including Biotechnology Product Director at Merck-Serono, Head of Pharma technical biotech transfer at Roche, where he managed the transfer of Avastin process manufacturing from Genentech and ...